Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 15/20 | 0.46 |
| ▸ | MMP7 | P09237 | 6/20 | 0.46 |
| ▸ | MMP3 | P08254 | 4/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 2/20 | 0.38 |
| ▸ | MMP15 | P51511 | 2/20 | 0.38 |
| ▸ | MMP16 | P51512 | 2/20 | 0.38 |
| ▸ | MMP26 | Q9NRE1 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021774 | 0.92 | LTA4H (0.43) | MMP1MMP7MMP3MMP2MMP9 | |
| SCHEMBL3536025 | 0.89 | CACNA1F (0.41) | MMP1MMP7MMP3MMP9ADAM17 | |
| SCHEMBL1021151 | 0.88 | MMP1 (0.41) | MMP1MMP7MMP3MMP2MMP9 | |
| SCHEMBL1020936 | 0.88 | MMP1 (0.47) | MMP1MMP7MMP3MMP2MMP9 | |
| SCHEMBL1021775 | 0.86 | LTA4H (0.42) | MMP1MMP7MMP3MMP2MMP9 | |
| SCHEMBL1020100 | 0.83 | LTA4H (0.39) | MMP1MMP7MMP3MMP9ADAM17 | |
| SCHEMBL1022551 | 0.81 | MMP1 (0.58) | MMP1MMP7MMP3MMP2MMP9 | |
| SCHEMBL1020682 | 0.80 | LTA4H (0.45) | MMP1MMP7MMP3LTA4HKCNH2 | |
| SCHEMBL1020938 | 0.79 | MMP1 (0.43) | MMP1MMP7MMP3MMP2MMP9 | |
| SCHEMBL1020684 | 0.76 | ESR1 (0.44) | MMP1MMP7MMP3LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869001-B1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | MMP9, MMP3, MMP2 | MMP1 9/4885MMP7 5/4885MMP3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.